Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18065790 | 0.79 | MAP3K14 (0.40) | MAP3K14CRBNCYP19A1DDB1LMNA | |
| SCHEMBL36369 | 0.78 | MAP3K14 (0.43) | MAP3K14CRBNIDO1CYP19A1DDB1 | |
| SCHEMBL5086277 | 0.77 | MAP3K14 (0.41) | MAP3K14CRBNCYP19A1DDB1MEN1 | |
| Water SCHEMBL27852712 | 0.77 | MAP3K14 (0.41) | MAP3K14CRBNCYP19A1DDB1MEN1 | |
| SCHEMBL30158537 | 0.77 | MAP3K14 (0.41) | MAP3K14CRBNCYP19A1DDB1MEN1 | |
| SCHEMBL4226226 | 0.77 | MAP3K14 (0.41) | MAP3K14CRBNCYP19A1DDB1MEN1 | |
| SCHEMBL11835120 | 0.74 | MAP3K14 (0.43) | MAP3K14CRBNIDO1CYP19A1DDB1 | |
| SCHEMBL11047080 | 0.74 | MAP3K14 (0.43) | MAP3K14CRBNIDO1CYP19A1DDB1 | |
| Bicarbonate SCHEMBL28576915 | 0.73 | MAP3K14 (0.39) | MAP3K14CRBNCYP19A1DDB1MEN1 | |
| SCHEMBL4226223 | 0.72 | MAP3K14 (0.41) | MAP3K14CRBNCYP19A1DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4380962-A1 | PROCESS FOR THE PREPARATION OF SEMAGLUTIDE | MSN Laboratories Private Limited, R&D Center (IN) | 2024-06-12 | — | — | EP | claimed |
| WO-2023012829-A1 | PROCESS FOR THE PREPARATION OF SEMAGLUTIDE | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2023-02-09 | — | — | WO | claimed |
| EP-2585818-A2 | METHOD AND APPARATUS FOR DETECTING AND REGULATING VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) BY FORMING A HOMEOSTATIC LOOP EMPLOYING A HALF-ANTIBODY BIOSENSOR | Shachar, Yehoshua (US) | 2013-05-01 | — | — | EP | disclosed |
| US-8415472-B2 | Water soluble photochromic compounds for labeling of biomolecules and method for detecting biomolecules using the same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2013-04-09 | — | — | US | disclosed |
| WO-2011163320-A9 | METHOD AND APPARATUS FOR DETECTING AND REGULATING VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) BY FORMING A HOMEOSTATIC LOOP EMPLOYING A HALF-ANTIBODY BIOSENSOR | PHARMACO-KINESIS CORPORATION (US) | 2012-02-16 | — | — | WO | disclosed |
| WO-2011163320-A2 | METHOD AND APPARATUS FOR DETECTING AND REGULATING VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) BY FORMING A HOMEOSTATIC LOOP EMPLOYING A HALF-ANTIBODY BIOSENSOR | PHARMACO-KINESIS CORPORATION (US) | 2011-12-29 | — | — | WO | disclosed |
| US-20100256397-A1 | WATER SOLUBLE PHOTOCHROMIC COMPOUNDS FOR LABELING OF BIOMOLECULES AND METHOD FOR DETECTING BIOMOLECULES USING THE SAME | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2010-10-07 | — | — | US | disclosed |
| WO-2009054608-A1 | WATER SOLUBLE PHOTOCHROMIC COMPOUNDS FOR LABELING OF BIOMOLECULES AND METHOD FOR DETECTING BIOMOLECULES USING THE SAME | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-04-30 | — | — | WO | disclosed |
| WO-2006091233-A2 | CELLULAR DELIVERY OF REAGENTS THAT INHIBIT GENE EXPRESSION UTILIZING THE ANTHRAX TOXIN PROTECTIVE ANTIGEN (PA) | BOSTON MEDICAL CENTER CORPORATION (US) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256397-A1 | WATER SOLUBLE PHOTOCHROMIC COMPOUNDS FOR LABELING OF BIOMOLECULES AND METHOD FOR DETECTING BIOMOLECULES USING THE SAME | MB, RBP1, TTR | MAP3K14 3184/4885CRBN 1796/4885IDO1 3256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.